Investment Thesis

. A price level below $50 or negative trial results would prompt a reevaluation of the position.

Competitive Moat

characterized primarily by intangible assets, notably its extensive portfolio of patents and proprietary formulations that underpin its leading-edge therapies. The regulatory barriers to entry in the biopharmaceutical sector further enhance this moat, as new entrants face significant hurdles in gaining approval for similar products. Over the next 5-10 years, this competitive advantage appears durable, although the emergence of biosimilars and increased competition from companies like Amgen and Roche pose notable threats.

Growth Engine

Future revenue growth for BMY is primarily driven by its expanding drug portfolio, which includes blockbuster therapies such as Revlimid and Eliquis. The total addressable market (TAM) in oncology and hematology is projected to grow significantly, with increasing patient populations and a rise in treatment rates. Additionally, geographic expansion, particularly in emerging markets, provides further avenues for organic growth. BMY is gaining market share, particularly in immuno-oncology, where it has established a leadership position.